** = Publications listed in SCI/SSCI/Pubmed
** Schwarzenberg, J; Czernin, J; Cloughesy, TF; Ellingson, BM; Pope, WB; Grogan, T; Elashoff, D; Geist, C; Silverman, DH; Phelps, ME; Chen, W
Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.
Clin Cancer Res. 2014; 20(13):3550-3559
Doi: 10.1158/1078-0432.CCR-13-1440
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Schwarzenberg, J; Czernin, J; Cloughesy, TF; Ellingson, BM; Pope, WB; Geist, C; Dahlbom, M; Silverman, DH; Satyamurthy, N; Phelps, ME; Chen, W
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
J Nucl Med. 2012; 53(1):29-36
Doi: 10.2967/jnumed.111.092387
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Schwarzenberg, J; Radu, CG; Benz, M; Fueger, B; Tran, AQ; Phelps, ME; Witte, ON; Satyamurthy, N; Czernin, J; Schiepers, C
Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.
Eur J Nucl Med Mol Imaging. 2011; 38(4):711-721
Doi: 10.1007/s00259-010-1666-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG